Silence Therapeutics

From Wikipedia, the free encyclopedia
Jump to: navigation, search
Silence Therapeutics PLC
Type Public (LSESLN)
Industry Pharmaceuticals
Founded 1994
Employees 50
Website www.silence-therapeutics.com

Silence Therapeutics (AIM:SLN[1]) is a biotechnology company that develops gene therapeutic technology based on RNA interference (RNAi). They are involved in developmental research of targeted RNAi therapeutics for the treatment of serious diseases. Formed in 1994 as a publicly traded drug research and development company, Silence Therapeutics has offices in London and Berlin, with its corporate headquarters based at 1 Lyric Square, London.

Profile[edit]

The targeting, delivery and on-going structural modification of sequences are the three platforms for Silence Therapeutics’s RNAi therapeutic development. These three platforms are:

Silence Therapeutics develops these structural modifications using three exclusive licences from the University of Massachusetts Amherst.

History[edit]

In 2005, the company acquired Atugen AG based in Germany, changing the company name to Silence Therapeutics AG. More recently in January 2010, Silence Therapeutics merged with Intradigm Corporation, a privately held biotechnology company in the United States that developed systematic RNA interference.[2]

Partnerships[edit]

Silence Therapeutics has multiple partnerships with other pharmaceutical companies, such as AstraZeneca, Pfizer/Quark Pharma and Dainippon Sumitomo.[3]

References[edit]

  1. ^ "Google Finance Stock Exchange listing for Silence Therapeutics". Retrieved 2011-09-16. 
  2. ^ "Stockopedia - Silence Therapeutics Company History". Stockopedia. Retrieved 2011-09-16. 
  3. ^ "Silence Therapeutics Collaborative Partnerships". Silence Therapeutics. Retrieved 2011-09-26. 

External links[edit]